Skip to main content

Table 2 Treatment effects

From: Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

 Streptozocin/5-FUPRRTEverolimus
OR n = 22SD n = 10p-valueOR n = 39SD n = 17p-valueOR n = 12SD n = 40p-value
Age years, median mean)63 (63)65 (65)1.062 (62)650,265 (65)67 (66)0,9
Sex, female (%)10 (83)2 (17)0,220 (77)6 (23)0,22 (17)19 (48)0,06
Ongoing SSA treatment (%)3 (14)00,521 (54)10 (59)0,77 (58)25 (63)0,8
Prior treatments Median (mean)0 (0,6)0 (0,6)1,02 (1,8)2 (2,2)0,12,5 (2,4)3 (2,7)0,7
Ki67% Median (IQR)
 Total group10 (10–13)10 (3–13)0,27 (3,5–10)6 (1–10)0,49 (3,5-11,5)9 (5–12)0,7
 Pancreas10 (8–13)10 (10–14)0,77 (4–12,5)10 (5,5–10)1,08 (5–13)10 (8,5-12,5)0,5
 Small intestinal6 (2,5-11,5)3 (1–8,5)0,46 (1,5–10)7 (3–11,5)0,4
Stage No. patients (%)
 Regional1 (5)1 (10)0,51 (3)00,51 (8)3 (8)0,9
 Distant21 (95)9 (90) 38 (97)17 (100) 11 (92)37 (92)
  1. Age, sex, ongoing somatostatin analogue-treatment, prior treatments, Ki 67% and stage for from patients divided into treatment modality and best treatment response; objective response or stable. For Ki 67% data is given for the total patient group and further subdivided into the most common primaries; pancreas and small intestine. SSA somatostatin analogue, IQR interquartile range